ORIC Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ORIC research report →
Companywww.oricpharma.com
ORIC Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations.
- CEO
- Jacob Chacko
- IPO
- 2020
- Employees
- 122
- HQ
- South San Francisco, CA, US
Price Chart
Valuation
- Market Cap
- $870.58M
- P/E
- -6.56
- P/S
- 0.00
- P/B
- 2.13
- EV/EBITDA
- -5.79
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -35.33%
- ROIC
- -35.78%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-129,468,000 · -1.27%
- EPS
- $-1.47 · 19.67%
- Op Income
- $-143,004,000
- FCF YoY
- -0.20%
Performance & Tape
- 52W High
- $14.93
- 52W Low
- $5.51
- 50D MA
- $10.25
- 200D MA
- $10.87
- Beta
- 1.10
- Avg Volume
- 1.95M
Get TickerSpark's AI analysis on ORIC
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 24, 26 | Piscitelli Dominic | other | 52,000 |
| Feb 24, 26 | Piscitelli Dominic | other | 52,000 |
| Feb 24, 26 | Piscitelli Dominic | sell | 52,000 |
| Jan 16, 26 | Heyman Richard A. | sell | 3,200 |
| Jan 16, 26 | Heyman Richard A. | sell | 3,500 |
| Jan 2, 26 | You Angie | other | 40,000 |
| Jan 2, 26 | Kunkel Lori Anne | other | 40,000 |
| Jan 2, 26 | Hoerter Steven L. | other | 40,000 |
| Jan 2, 26 | Heyman Richard A. | other | 40,000 |
| Jan 2, 26 | Dier Mardi | other | 40,000 |
Our ORIC Coverage
We haven't published any research on ORIC yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ORIC Report →